Mortality, Hospital Stays, Costs All Down Among U.S. Seniors

This article originally appeared here.
Share this content:
Mortality, Hospital Stays, Costs All Down Among U.S. Seniors
Mortality, Hospital Stays, Costs All Down Among U.S. Seniors

(HealthDay News) -- Between 1999 and 2013, yearly mortality and hospitalization rates steadily declined among Americans in the traditional fee-for-service Medicare program. Meanwhile, spending on inpatient care showed the same pattern. The findings were published in the July 28 issue of the Journal of the American Medical Association.

Harlan Krumholz, M.D., a professor of medicine at the Yale University School of Medicine in New Haven, Conn., and colleagues focused on the traditional Medicare fee-for-service program, because it has the most data available. In 2013, about 71 percent of Medicare beneficiaries were in the traditional fee-for-service program, the authors reported. The rest were enrolled in newer, Medicare Advantage plans, where private insurers approved by Medicare provide coverage. Krumholz's team was also able to analyze mortality rates among Americans in Medicare Advantage plans.

In 1999, Medicare beneficiaries' all-cause mortality rate was 5.3 percent; by 2013, that figure had declined to 4.5 percent. Mortality rates dropped both in and out of hospitals. Meanwhile, hospitalizations fell from 35,274 per 100,000 annually to 26,930 per 100,000. Inpatient spending dropped from $3,290 per person in 1999, to $2,801 in 2013 (adjusted for inflation).

Progress is being made, at least for Medicare beneficiaries, Krumholz told HealthDay. "That should give the public some confidence that we're going in the right direction," he added. "But we shouldn't become complacent, either." And while some trends are "unequivocally good" -- such as the declining mortality rate -- some others are tougher to interpret, Krumholz said. His team looked at what happened to beneficiaries after they were discharged from the hospital, and found changing patterns over time. By 2013, more people were discharged to skilled nursing facilities, long-term care, hospice, or home health services. Fewer were sent home without health services. Louise Sheiner, Ph.D., a senior fellow in economic studies at the Brookings Institution, a Washington, D.C.-based think tank, told HealthDay that what's not clear from the study is whether those changes improved people's lives, or were cost-effective.

One author disclosed financial ties to Medtronic, Johnson & Johnson, and UnitedHealth.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »